AstraZeneca PLC $AZN Shares Purchased by Nissay Asset Management Corp Japan ADV

Key Points

• Nissay Asset Management Corp Japan ADV increased its holdings in AstraZeneca PLC by 20.4% during the first quarter, bringing its total to 71,272 shares valued at approximately $5.24 million.
• AstraZeneca reported a net revenue of $14.46 billion for the last quarter, exceeding analysts' expectations, while earnings per share matched estimates at $1.09.
• The company recently announced a semi-annual dividend of $0.505 to be paid on September 8th, reflecting a yield of 200%, alongside a dividend payout ratio of 37.97%.

Nissay Asset Management Corp Japan ADV increased its holdings in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 20.4% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 71,272 shares of the company's stock after acquiring an additional 12,059 shares during the period. Nissay Asset Management Corp Japan ADV's holdings in AstraZeneca were worth $5,238,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the business. NewEdge Advisors LLC grew its position in shares of AstraZeneca by 2.0% during the 1st quarter. NewEdge Advisors LLC now owns 73,882 shares of the company's stock valued at $5,430,000 after acquiring an additional 1,414 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of AstraZeneca by 6.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 489,083 shares of the company's stock valued at $35,948,000 after acquiring an additional 30,452 shares during the period. Hancock Whitney Corp grew its position in shares of AstraZeneca by 2.4% during the 1st quarter. Hancock Whitney Corp now owns 11,009 shares of the company's stock valued at $809,000 after acquiring an additional 262 shares during the period. Cinctive Capital Management LP grew its position in shares of AstraZeneca by 4.5% during the 1st quarter. Cinctive Capital Management LP now owns 88,446 shares of the company's stock valued at $6,501,000 after acquiring an additional 3,793 shares during the period. Finally, Clark Capital Management Group Inc. grew its position in shares of AstraZeneca by 3,793.4% during the 1st quarter. Clark Capital Management Group Inc. now owns 391,169 shares of the company's stock valued at $28,751,000 after acquiring an additional 381,122 shares during the period. 20.35% of the stock is currently owned by institutional investors and hedge funds.

AstraZeneca Trading Down 0.1%

Shares of AstraZeneca stock opened at $81.70 on Friday. The firm has a market capitalization of $253.38 billion, a PE ratio of 30.71, a P/E/G ratio of 1.50 and a beta of 0.37. AstraZeneca PLC has a twelve month low of $61.24 and a twelve month high of $84.30. The firm's 50-day moving average price is $74.90 and its 200 day moving average price is $72.74. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.55.

AstraZeneca (NASDAQ:AZN - Get Free Report) last issued its quarterly earnings results on Tuesday, July 29th. The company reported $1.09 earnings per share for the quarter, meeting analysts' consensus estimates of $1.09. The firm had revenue of $14.46 billion for the quarter, compared to analyst estimates of $14.08 billion. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. AstraZeneca's quarterly revenue was up 16.1% compared to the same quarter last year. During the same period last year, the company posted $1.24 EPS. On average, sell-side analysts predict that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

AstraZeneca Cuts Dividend

The firm also recently announced a semi-annual dividend, which will be paid on Monday, September 8th. Shareholders of record on Friday, August 8th will be paid a $0.505 dividend. This represents a yield of 200.0%. The ex-dividend date of this dividend is Friday, August 8th. AstraZeneca's dividend payout ratio (DPR) is 37.97%.

Analysts Set New Price Targets

Separately, Berenberg Bank set a $97.00 price target on shares of AstraZeneca in a research note on Wednesday, July 9th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, AstraZeneca presently has an average rating of "Moderate Buy" and an average target price of $86.00.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.